Buy Vivjoa (oteseconazole)

What is Vivjoa (oteseconazole) for?

Vivjoa (oteseconazole) is an antifungal medicine indicated to reduce the risk of vaginal yeast infections that keep coming back (recurrent vulvovaginal candidiasis, RVVC) in women with a history of RVVC. It should only be taken by females who are not pregnant and who are not able to become pregnant.^[1]

It is available in capsule form containing 150 mg of oteseconazole.^[1]

How does Vivjoa (oteseconazole) work?

Repeated yeast infections are traditionally treated with antifungal medication fluconazole. However, using fluconazole can have health risks, especially when used for longer time periods. Another risk is that the yeasts causing the infection can become resistant to the drug.^[2]

The active ingredient in Vivjoa, oteseconazole, can inhibit fungal CYP51. This is an enzyme that is involved in building fungal cell walls and it helps fungal cells withstand stressful environments. Blocking CYP51 releases proteins which are toxic to fungi, and helps reduce fungal growth.^[2]

Vivjoa is designed in a way that it inhibits human CYP enzymes much less than other antifungal drugs and thereby has lower health risks.^[2]

Where has Vivjoa (oteseconazole) been approved?

Vivjoa (oteseconazole) was approved for the treatment of RVCC in women by:

• The Food and Drug Administration (FDA), USA, on April 28, 2022.^[1]

The FDA granted Vivjoa with Priority Review, and with Qualified Infectious Disease Product and Fast Track designations.^[3]

Please note that this medicine may have also been approved in other regions than the ones we’ve listed. If you have a question about its approval in a specific country feel free to contact our support team. /contact-us

How is Vivjoa (oteseconazole) taken?

Vivjoa can be used using two different dosage regimens: Vivjoa only, or Vivjoa plus fluconazole. Your treating doctor will determine what is the best dosage regimen for you.^[1]

The standard dosage for the Vivjoa-only dosage regimen is:^[1]

• • On Day 1: 600 mg (four capsules), by mouth, then
  • On Day 2: 450 mg (three capsules), by mouth, then
  • On Day 14: 150 mg (one capsule) once a week (every 7 days) by mouth for 11 weeks.

The standard dosage for the Vivjoa-only dosage regimen is:^[1]

• • • On Day 1, Day 4, and Day 7: 150 mg (one capsule) by mouth, then
    • On Days 14 through 20: 150 mg (one capsule) by mouth once each day for 7 days, then
    • On Day 28: 150 mg (one capsule) by mouth once a week (every 7 days) for 11 weeks.

Take Vivjoa capsules by mouth with food. Swallow the capsules whole. Do not chew, crush, dissolve, or open the capsules.^[1]

Complete information about Vivjoa (oteseconazole) dosage and administration can be found in the official prescribing information listed in our references section.^[1]

Note: Please consult with your treating doctor for personalised dosing.

Are there any known adverse reactions or side effects of Vivjoa (oteseconazole)?

Common adverse reactions

The most common side effects (>2% of patients) listed in the prescribing information include:^[1]

• • • Headache
    • Nausea

Serious adverse reactions

The serious adverse reactions listed in the prescribing information include:^[1]

• • • Heart failure

Use in a specific population

Women who are pregnant, are able to become pregnant, and women who are breastfeeding should not take Vivjoa (oteseconazole). Vivjoa may harm your unborn baby.^[1]

Before you start treatment with Vivjoa, tell your treating doctor about all of your medical conditions, including if you have kidney or liver problems.^[1]

Tell your treating doctor about all the medicines you take, especially if you take medicines called breast cancer resistance protein (BCRP) transporter substrates, including the cholesterol lowering drug rosuvastatin. Taking Vijoa together with BCRP transporter substrates may increase your risk of developing side effects.^[1]

For a comprehensive list of side effects and adverse reactions please refer to the official prescribing information.^[1]

References

1. Full prescribing information [FDA]: Vivjoa (oteseconazole) [PDF] Mycovia Pharmaceuticals, Apr 2022

2. Oteseconazole: an advance in treatment of recurrent vulvovaginal candidiasis
Sobel JD et al., Future Microbiology, Nov 2021

3. FDA Approves Vivjoa (Oteseconazole) for Chronic Yeast Infections
Press release, Apr 2022